Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial (vol 43, pg 465, 2024)

被引：0
|
作者：
Espay, A. J.
Stocchi, F.
Pahwa, R.
机构：
来源：
LANCET NEUROLOGY | 2024年 / 23卷 / 06期
关键词：
D O I：
10.1016/S1474-4422(24)00172-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial
    Facheris, Maurizio
    Robieson, Weining
    Fisseha, Nahome
    Standaert, David
    NEUROLOGY, 2021, 96 (15)
  • [22] Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial
    Facheris, Maurizio
    Robieson, Weining
    Fisseha, Nahome
    Standaert, David
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 331 - 331
  • [23] iNDiGO: A Multicenter, Randomized, Double-blind, Placebo-controlled, Study of Continuous ND0612 Infusion with Adjunct Oral Levodopa in Fluctuating Parkinson's Disease
    LeWitt, Peter
    Stocchi, Fabrizio
    Isaacson, Stuart
    Leionen, Mika
    Rachmilewitz, Tami
    Case, Ryan
    Kieburtz, Karl
    Olanow, C. Warren
    MOVEMENT DISORDERS, 2018, 33 : S94 - S94
  • [24] Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
    Katzenschlager, Regina
    Poewe, Werner
    Rascol, Olivier
    Trenkwalder, Claudia
    Deuschl, Gunther
    Chaudhuri, K. Ray
    Henriksen, Tove
    van Laar, Teus
    Spivey, Kevin
    Vel, Senthil
    Staines, Harry
    Lees, Andrew
    LANCET NEUROLOGY, 2018, 17 (09): : 749 - 759
  • [25] Subcutaneous foslevodopa/foscarbidopa in patients with advanced Parkinson's Disease: results from a randomized, double-blind, double-dummy phase 3 trial
    Soileau, M.
    Spindler, M.
    Aldred, J.
    Budur, K.
    Fisseha, N.
    Fung, V.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Litvan, I.
    O'Neill, D.
    Robieson, W.
    Standaert, D.
    Talapala, S.
    Vaou, E. Okeanis
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2022, 37 : S354 - S354
  • [26] Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
    Hauser, Robert A.
    Hsu, Ann
    Kell, Sherron
    Espay, Alberto J.
    Sethi, Kapil
    Stacy, Mark
    Ondo, William
    O'Connell, Martin
    Gupta, Suneel
    LANCET NEUROLOGY, 2013, 12 (04): : 346 - 356
  • [27] A double-blind, randomised, placebo-controlled trial to investigate the efficacy and safety of nebicapone in levodopa-treated Parkinson's disease patients with motor fluctuations
    Ferreira, J. J.
    Rascol, O.
    Poewe, W.
    Sampaio, C.
    Rocha, F.
    Nunes, T.
    Almeida, L.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2008, 23 (01) : S195 - S195
  • [28] Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial
    Reinisch, Walter
    Angelberger, Sieglinde
    Petritsch, Wolfgang
    Shonova, Olga
    Lukas, Milan
    Bar-Meir, Simon
    Teml, Alexander
    Schaeffeler, Elke
    Schwab, Matthias
    Dilger, Karin
    Greinwald, Roland
    Mueller, Ralph
    Stange, Eduard F.
    Herrlinger, Klaus R.
    GUT, 2010, 59 (06) : 752 - 759
  • [29] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Soileau, Michael J.
    Aldred, Jason
    Budur, Kumar
    Fisseha, Nahome
    Fung, Victor Sc
    Jeong, Anna
    Kimber, Thomas E.
    Klos, Kevin
    Litvan, Irene
    O'Neill, Daniel
    Robieson, Weining Z.
    Spindler, Meredith A.
    Standaert, David G.
    Talapala, Saritha
    Vaou, Eleni Okeanis
    Zheng, Hui
    Facheris, Maurizio F.
    Hauser, Robert A.
    LANCET NEUROLOGY, 2022, 21 (12): : 1099 - 1109
  • [30] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial (vol 21, pg 1099, 2022)
    Soileau, M. J.
    Aldread, J.
    Budur, K.
    LANCET NEUROLOGY, 2023, 22 (03): : E5 - E5
12345